0001752724-22-278002.txt : 20221213 0001752724-22-278002.hdr.sgml : 20221213 20221213132559 ACCESSION NUMBER: 0001752724-22-278002 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221213 DATE AS OF CHANGE: 20221213 EFFECTIVENESS DATE: 20221213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEKLA HEALTHCARE INVESTORS CENTRAL INDEX KEY: 0000805267 IRS NUMBER: 046564285 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-04889 FILM NUMBER: 221459178 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6177728515 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: H&Q HEALTHCARE INVESTORS DATE OF NAME CHANGE: 19920703 N-CEN 1 primary_doc.xml X0404 N-CEN LIVE 0000805267 XXXXXXXX 811-04889 false false false N-2 TEKLA HEALTHCARE INVESTORS 811-04889 0000805267 549300SNASESIFOS6V75 100 FEDERAL STREET, 19TH FLOOR BOSTON 02110 US-MA US 617-772-8500 Tekla Capital Management LLC 100 Federal Street 19th Floor Boston 02110 617-772-8500 Fund Administration Records State Street Bank and Trust Company 1 Lincoln Street Boston 02111 617-786-3000 Accounting and Custody Records N N N-2 N Thomas M. Kent, CPA N/A N Rakesh K. Jain, Ph.D. N/A N W. Mark Watson, CPA N/A N Daniel R. Omstead, Ph.D. N/A Y Jeffrey A. Bailey N/A N Kathleen L. Goetz N/A N Laura Woodward, CPA N/A 100 Federal Street, 19th Floor Boston 02110 XXXXXX N N N N N N Deloitte & Touche LLP 34 00000000000000000000 N N N N N N TEKLA HEALTHCARE INVESTORS 549300SNASESIFOS6V75 N 0 0 0 N/A Y N Y N N Goldman Sachs Bank USA KD3XUN7C6T14HNAYLU02 N N Cash collateral reinvestment fee Revenue sharing split 10691999.41000000 172166.00000000 Rule 18f-4(e) (17 CFR 270.18f-4(e)) Rule 18f-4 (17 CFR 270.18f-4) Rule 17a-6 (17 CFR 270.17a-6) N N N N Tekla Capital Management LLC 801-61018 000119626 254900YSXGYL9SE8C952 N Computershare Trust Company, National Association 85-11340 2549001YYB62BVMSAO13 N N N Refinitiv US Holdings Inc. 549300NF240HXJO7N016 N Ice Data Services, Inc. 13-3668779 Tax ID N N Credit Suisse (Schweiz) AG 549300CWR0W0BCS9Q144 CH N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) State Street Bank and Trust Company (Edinburgh, GB, Branch) 571474TGEMMWANRLN572 GB N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) BNP Paribas Securities Services 549300WCGB70D06XZS54 FR N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Clearstream Banking S.A. 549300OL514RA0SXJJ44 LU N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) State Street Bank and Trust Company (Boston, MA, US, Branch) 571474TGEMMWANRLN572 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N Computershare Trust Company, National Association 2549001YYB62BVMSAO13 N N N State Street Bank and Trust Company (Boston, MA, US, Branch) 571474TGEMMWANRLN572 N N N Morgan Stanley & Co. LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 5322.69000000 Sanford C. Bernstein & Co., LLC 8-52942 000104474 549300I7JYZHT7D5CO04 8054.85000000 Stifel, Nicolaus & Company, Incorporated 8-1447 000000793 5WUVMA08EYG4KEUPW589 8409.84000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 47957.08000000 Pershing LLC 8-17574 000007560 ZI8Q1A8EI8LQFJNM0D94 57313.62000000 Mizuho Securities USA LLC 8-37710 000019647 7TK5RJIZDFROZCA6XF66 8368.47000000 Oppenheimer & Co. Inc. 8-4077 000000249 254900VH02JQR2L8XD64 11350.20000000 Jefferies LLC 8-15074 000002347 58PU97L1C0WSRCWADL48 20906.73000000 Wells Fargo Securities, LLC 8-65876 000126292 VYVVCKR63DVZZN70PB21 9996.21000000 National Financial Services LLC 8-26740 000013041 549300JRHF1MHHWUAW04 31357.02000000 229393.16000000 Hotspot Therapeutics, Inc. N/A N/A 00000000000000000000 2049525.72000000 Moonlake Immunotherapeutics N/A N/A 00000000000000000000 2058000.00000000 ReCode Therapeutics, Inc. N/A N/A 00000000000000000000 2719999.17000000 Quell Therapeutics Limited N/A N/A 2138003MLPFKHCR6UX19 GB 2936362.59000000 Invetx, Inc. N/A N/A 00000000000000000000 2069999.88000000 ENDEAVOR BIOMEDICINES N/A N/A 00000000000000000000 3099996.29000000 Priothera Limited N/A N/A 00000000000000000000 IE 2946770.78000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 109161727.77000000 State Street Bank and Trust Company N/A N/A 571474TGEMMWANRLN572 7902573000.00000000 Jefferies LLC 8-15074 000002347 58PU97L1C0WSRCWADL48 2572800.00000000 8037436833.40000000 N 1008617737.90000000 Common stock Tekla Healthcare Investors N N N N N N 0.99000000 1.19000000 17.28000000 19.36000000 true INTERNAL CONTROL RPT 2 NCEN_811-04889_24315571_0922.htm n-cenletterhqh2022.htm - Generated by SEC Publisher for SEC Filing

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Trustees of Tekla Healthcare Investors:

In planning and performing our audit of the financial statements of Tekla Healthcare Investors (the "Fund") as of and for the year ended September 30, 2022, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund's internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion.

The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A fund's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A fund's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the fund; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the fund are being made only in accordance with authorizations of management and trustees of the fund; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of a fund's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Fund’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness, as defined above, as of September 30, 2022.

This report is intended solely for the information and use of management and the Board of Trustees of the Fund and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.

/s/ DELOITTE & TOUCHE LLP

Boston, Massachusetts

November 21, 2022